PREVACID 15 MG
LANSOPRAZOLE : 15 MG · DIN 02165503 · TAKEDA PHARMACEUTICALS AMERICA INC
Health Canada status: MARKETED
What is PREVACID?
PREVACID 15 MG contains LANSOPRAZOLE : 15 MG. It is listed in the Health Canada Drug Product Database under DIN 02165503, held by TAKEDA PHARMACEUTICALS AMERICA INC, supplied as CAPSULE (DELAYED RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 10-Oct-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PREVACID used for?
PREVACID® (lansoprazole delayed-release capsules) and PREVACID® FasTab (lansoprazole delayed-release tablets) are indicated in the treatment of conditions where a reduction of gastric acid secretion is required, such as: Duodenal ulcer, Gastric ulcer, Reflux esophagitis including patients with Barrett's esophagus, and patients poorly responsive to an adequate course of therapy with histamine H2-receptor antagonists, Healing of non-steroidal anti-inflammatory drug (NSAID)-associated gastric ulcer; treatment of NSAID-associated gastric ulcer in patients who continue NSAID use, Reduction of risk of NSAID-associated gastric ulcers in patients with a history of gastric ulcers who require to continue taking a NSAID, Symptomatic Gastroesophageal Reflux Disease (GERD); treatment of heartburn and other symptoms associated with GERD, Pathological hypersecretory conditions including Zollinger-Ellison Syndrome, Eradication of Helicobacter pylori (H. pylori). PREVACID® is indicated for treatment of erosive and non-erosive GERD in children, aged 1 to 17 years.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02165503 |
|---|---|
| Brand name | PREVACID |
| Generic / active ingredient | LANSOPRAZOLE : 15 MG |
| Manufacturer | TAKEDA PHARMACEUTICALS AMERICA INC |
| Strength | 15 MG |
| Dosage form | CAPSULE (DELAYED RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A02BC03 LANSOPRAZOLE |
| AHFS class | 56:28.36 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 10-Oct-2008 |
| Original market date | 1995-12-31 00:00:00 |
How is it stored and handled?
null
How is it supplied?
PREVACID® 15 mg capsules are available in bottles of 30 and 100. PREVACID® 30 mg capsules are available in bottles of 30 and 100. PREVACID® FasTab 15 mg tablets are available in blister packages of 30. PREVACID® FasTab 30 mg tablets are available in blister packages of 30 and 100.
Is LANSOPRAZOLE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by SANIS HEALTH INC (Tier 3 Drug Shortages About & Resources), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code A02BC03 LANSOPRAZOLE. 19 of 41 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-LANSOPRAZOLE | 15 MG | CAPSULE (DELAYED RELEASE) | APOTEX INC | MARKETED | DIN 02293811 |
| APO-LANSOPRAZOLE | 30 MG | CAPSULE (DELAYED RELEASE) | APOTEX INC | MARKETED | DIN 02293838 |
| LANSOPRAZOLE | 15 MG | CAPSULE (DELAYED RELEASE) | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02385767 |
| LANSOPRAZOLE | 15 MG | CAPSULE (DELAYED RELEASE) | SANIS HEALTH INC | MARKETED | DIN 02357682 |
| LANSOPRAZOLE | 30 MG | CAPSULE (DELAYED RELEASE) | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02410389 |
| LANSOPRAZOLE | 30 MG | CAPSULE (DELAYED RELEASE) | SANIS HEALTH INC | MARKETED | DIN 02357690 |
| MYLAN-LANSOPRAZOLE | 15 MG | CAPSULE (DELAYED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02353830 |
| MYLAN-LANSOPRAZOLE | 30 MG | CAPSULE (DELAYED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02353849 |
| PREVACID | 30 MG | CAPSULE (DELAYED RELEASE) | TAKEDA PHARMACEUTICALS AMERICA INC | MARKETED | DIN 02165511 |
| PREVACID FASTAB | 15 MG | TABLET (DELAYED-RELEASE) | TAKEDA PHARMACEUTICALS AMERICA INC | MARKETED | DIN 02249464 |
Who else supplies LANSOPRAZOLE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LANSOPRAZOLE appears in 387 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.